His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy

Status: Completed
Location: See all (8) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this study is to compare the effectiveness of pacing from a physiologic His bundle (HB) lead position versus with the standard coronary sinus (CS) lead position in subjects with heart failure undergoing cardiac resynchronization therapy (CRT). While placement of left ventricular leads via the coronary sinus has anatomic limitations, we hypothesis that the achievement of QRS narrowing with His bundle capture will be superior for improving systolic function by echocardiographic indices (ejection fraction and strain) and quality of life and decreased rehospitalization and mortality.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients at least 18 years of age

• LV systolic dysfunction with LVEF ≤ 35%

• Evidence of intraventricular conduction delay with QRS duration \> 120 msec

• NYHA Class II, III, and ambulatory Class IV heart failure with either ischemic or nonischemic cardiomyopathy and patients with NYHA Class I symptoms and ischemic cardiomyopathy

• Left ventricular ejection fraction (LVEF) ≤ 35%, sinus rhythm (SR), left bundle-branch block (LBBB) morphology, and QRS duration ≥ 150 msec, and NYHA Class II, III, or ambulatory Class IV patients on goal-directed medical therapy (GDMT) \[Class I\]

• LVEF ≤ 35%, SR with LBBB with QRS 120-149 msec on GDMT \[Class IIa\]

• LVEF ≤ 35%, SR with non-LBBB with QRS ≥ 150 msec on GDMT \[Class IIa\]

• LVEF ≤ 35%, in AF if medication or AV nodal ablation will allow near 100% pacing \[Class IIa\]

• LVEF ≤ 35% undergoing new or replacement device with anticipated \>40% ventricular pacing on GDMT \[Class IIa\]

• LVEF ≤ 30%, ischemic etiology of HF, SR with LBBB ≥ 150 msec and NYHA Class I symptoms on GDMT \[Class IIb\]

• LVEF ≤ 35%, SR with non-LBBB with QRS 120-149 msec, NYHA Class III/ambulatory Class IV HF on GDMT \[Class IIb\] LVEF ≤ 35%, SR with non-LBBB with QRS ≥ 150 msec, NYHA Class II HF on GDMT \[Class IIb\]

Locations
United States
California
The University of California, Los Angeles
Los Angeles
Illinois
Northwestern University
Chicago
Rush University Medical Center
Chicago
The University of Chicago
Chicago
Edward Hospital
Naperville
Indiana
Indiana University
Indianapolis
Kentucky
Baptist Health Louisville
Louisville
Pennsylvania
Geisinger Wyoming Valley Medical Center
Wilkes-barre
Time Frame
Start Date: 2016-05-17
Completion Date: 2020-07-31
Participants
Target number of participants: 41
Treatments
Active_comparator: His Bundle Pacing
Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
Active_comparator: Coronary Sinus Pacing
Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
Related Therapeutic Areas
Sponsors
Collaborators: Indiana University, Geisinger Clinic, Baptist Health, Louisville, Northwestern University, Edward Hospital, University of California, Los Angeles, Rush University Medical Center
Leads: University of Chicago

This content was sourced from clinicaltrials.gov